Tildrakizumab as a Potential Option for Early Psoriatic Arthritis in Patients with Metabolic Comorbidities and Psoriasis: a Case Series
Tildrakizumab confirmed its efficacy in reducing signs and symptoms of early PsA, with high safety profile in our psoriasis patients also affected by multiple metabolic comorbidities.
Authors
- Diego Orsini (ORCID: https://orcid.org/0000-0002-3190-3988)
- Caterina Lanna (ORCID: https://orcid.org/0000-0002-3485-6275)
- Sara Lambiase (ORCID: https://orcid.org/0000-0003-4401-9865)
- Antonia Rivieccio
- Fabio Artosi (ORCID: https://orcid.org/0000-0002-7636-3532)
- Ruslana Gaeta Shumak (ORCID: https://orcid.org/0000-0002-7289-3026)
- Luigi Bianchi (ORCID: https://orcid.org/0000-0001-8724-9092)
- Cristiana Borselli
- Laura Diluvio (ORCID: https://orcid.org/0000-0003-1844-9052)
- Elena Campione (ORCID: https://orcid.org/0000-0001-7447-6798)
- Gaetana Costanza (ORCID: https://orcid.org/0000-0002-1115-4270)
Institutions
- University of Rome Tor Vergata (IT)
- San Gallicano Hospital (IT)
Publication Details
- Journal
- Dermatology Practical & Conceptual
- Published
- 2025-10-31
- DOI
- https://doi.org/10.5826/dpc.1504a5570
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80